These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 25130971)

  • 1. [Effect of PI3K/AKT pathway on cisplatin resistance in non-small cell lung cancer].
    Zhang Y; Lu H; Xu G
    Zhongguo Fei Ai Za Zhi; 2014 Aug; 17(8):635-42. PubMed ID: 25130971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of cisplatin resistance by inhibiting PI3K/Akt signal pathway in human lung cancer cells.
    Zhang Y; Bao C; Mu Q; Chen J; Wang J; Mi Y; Sayari AJ; Chen Y; Guo M
    Neoplasma; 2016; 63(3):362-70. PubMed ID: 26925782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR.
    Li B; Ding CM; Li YX; Peng JC; Geng N; Qin WW
    Oncol Rep; 2018 Mar; 39(3):1227-1234. PubMed ID: 29344640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
    Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
    Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PAX6-ZEB2 axis promotes metastasis and cisplatin resistance in non-small cell lung cancer through PI3K/AKT signaling.
    Wu DM; Zhang T; Liu YB; Deng SH; Han R; Liu T; Li J; Xu Y
    Cell Death Dis; 2019 Apr; 10(5):349. PubMed ID: 31024010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
    Gong T; Cui L; Wang H; Wang H; Han N
    J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
    Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-29c reduces the cisplatin resistance of non-small cell lung cancer cells by negatively regulating the PI3K/Akt pathway.
    Sun DM; Tang BF; Li ZX; Guo HB; Cheng JL; Song PP; Zhao X
    Sci Rep; 2018 May; 8(1):8007. PubMed ID: 29789623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of PI3K/Akt pathway by G protein-coupled receptor 37 promotes resistance to cisplatin-induced apoptosis in non-small cell lung cancer.
    Liu H; Zhu Y; Niu H; Jie J; Hua S; Bai X; Wang S; Song L
    Cancer Med; 2023 Oct; 12(19):19777-19793. PubMed ID: 37732632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
    Gao BB; Wang SX
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A; Li H; Li R; Lu L; Wu X
    Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
    Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
    Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumor activity of Shikonin against afatinib resistant non-small cell lung cancer via negative regulation of PI3K/Akt signaling pathway.
    Li B; Yuan Z; Jiang J; Rao Y
    Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30420490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Klotho sensitizes human lung cancer cell line to cisplatin via PI3k/Akt pathway.
    Wang Y; Chen L; Huang G; He D; He J; Xu W; Zou C; Zong F; Li Y; Chen B; Wu S; Zhao W; Wu J
    PLoS One; 2013; 8(2):e57391. PubMed ID: 23437382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The study of PI3K/AKT pathway in lung cancer metastasis and drug resistance].
    Zhu B; Zhou X
    Zhongguo Fei Ai Za Zhi; 2011 Aug; 14(8):689-94. PubMed ID: 21859552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CNTN-1 Enhances Chemoresistance in Human Lung Adenocarcinoma Through Induction of Epithelial-Mesenchymal Transition by Targeting the PI3K/Akt Pathway.
    Zhang R; Sun S; Ji F; Liu C; Lin H; Xie L; Yang H; Tang W; Zhou Y; Xu J; Li P
    Cell Physiol Biochem; 2017; 43(2):465-480. PubMed ID: 28934754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin resistance in lung cancer is mediated by MACC1 expression through PI3K/AKT signaling pathway activation.
    Zhang Q; Zhang B; Sun L; Yan Q; Zhang Y; Zhang Z; Su Y; Wang C
    Acta Biochim Biophys Sin (Shanghai); 2018 Aug; 50(8):748-756. PubMed ID: 29961813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COX-2 potentiates cisplatin resistance of non-small cell lung cancer cells by promoting EMT in an AKT signaling pathway-dependent manner.
    Jiang GB; Fang HY; Tao DY; Chen XP; Cao FL
    Eur Rev Med Pharmacol Sci; 2019 May; 23(9):3838-3846. PubMed ID: 31115011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer.
    Cortés-Sempere M; de Miguel MP; Pernía O; Rodriguez C; de Castro Carpeño J; Nistal M; Conde E; López-Ríos F; Belda-Iniesta C; Perona R; Ibanez de Caceres I
    Oncogene; 2013 Mar; 32(10):1274-83. PubMed ID: 22543588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
    Cortes-Sempere M; Chattopadhyay S; Rovira A; Rodriguez-Fanjul V; Belda-Iniesta C; Tapia M; Cejas P; Machado-Pinilla R; Manguan-García C; Sánchez-Pérez I; Nistal M; Moratilla C; de Castro-Carpeño J; Gonzalez-Barón M; Albanell J; Perona R
    Cancer Lett; 2009 Dec; 286(2):206-16. PubMed ID: 19553005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.